Furthermore, both GLP-1 RAs and SGLT-2 inhibitors have anti-obesity effects, in contrast to the effects of some other anti-glycemic agents, such as insulin, the use of which tends to be associated with increases in the body mass of patients. The gene discussed is SLC5A2; the disease is obesity due to melanocortin 4 receptor deficiency.